Esperion Therapeutics ESPR Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingCostsAndExpenses.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's total costs & expenses?
- Esperion Therapeutics (ESPR) reported total costs & expenses of $32.31M in Q4 2025.
- How has Esperion Therapeutics's total costs & expenses changed year-over-year?
- Esperion Therapeutics's total costs & expenses increased by 88.4% year-over-year, from $17.15M to $32.31M.
- What is the long-term trend for Esperion Therapeutics's total costs & expenses?
- Over 2 years (2023 to 2025), Esperion Therapeutics's total costs & expenses has grown at a 72.8% compound annual growth rate (CAGR), from $43.27M to $129.22M.
- What does total costs & expenses mean?
- This metric represents the aggregate of all operating and non-operating costs incurred by the company to support its business activities, including cost of goods sold, research and development, and selling, general, and administrative expenses. It serves as a comprehensive measure of the total resource consumption required to maintain operations and drive commercialization efforts. Monitoring this figure helps investors assess the company's overall cost structure and operational efficiency relative to its revenue generation.